カテゴリ： 世界, 医療/バイオ, QYResearch

組換えヒト凝固VIIaの世界市場2023年：プレフィルドシリンジ、バイアル

■ 英語タイトル：Global Recombinant Human Coagulation VIIa Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8881）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8881
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：67
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[組換えヒト凝固VIIaの世界市場2023年：プレフィルドシリンジ、バイアル]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料は組換えヒト凝固VIIaのグローバル市場について調査・分析し、世界の組換えヒト凝固VIIa市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（プレフィルドシリンジ、バイアル）、用途別セグメント分析（先天性血友病、後天性血友病、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Novo Nordisk、LFB SA HEMA Biologics、AryoGen Pharmed、GENERIUMなどが含まれています。組換えヒト凝固VIIaのグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、組換えヒト凝固VIIa市場規模を算出する際に考慮しました。

・組換えヒト凝固VIIa市場の概要
- 製品の定義
- 組換えヒト凝固VIIaの種類別セグメント
- 世界の組換えヒト凝固VIIa市場規模：タイプ別分析（プレフィルドシリンジ、バイアル）
- 組換えヒト凝固VIIaの用途別セグメント
- 世界の組換えヒト凝固VIIa市場規模：用途別分析（先天性血友病、後天性血友病、その他）
- 世界の組換えヒト凝固VIIa市場規模予測（2018年-2029年）
- 組換えヒト凝固VIIaの平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 組換えヒト凝固VIIa市場の競争状況およびトレンド

・組換えヒト凝固VIIaの地域別市場規模
- 北米の組換えヒト凝固VIIa市場規模（2018年-2029年）
- 米国の組換えヒト凝固VIIa市場規模（2018年-2029年）
- ヨーロッパの組換えヒト凝固VIIa市場規模（2018年-2029年）
- アジア太平洋の組換えヒト凝固VIIa市場規模（2018年-2029年）
- 中国の組換えヒト凝固VIIa市場規模（2018年-2029年）
- 日本の組換えヒト凝固VIIa市場規模（2018年-2029年）
- 韓国の組換えヒト凝固VIIa市場規模（2018年-2029年）
- インドの組換えヒト凝固VIIa市場規模（2018年-2029年）
- オーストラリアの組換えヒト凝固VIIa市場規模（2018年-2029年）
- 中南米の組換えヒト凝固VIIa市場規模（2018年-2029年）
- 中東・アフリカの組換えヒト凝固VIIa市場規模（2018年-2029年）

・種類別セグメント：プレフィルドシリンジ、バイアル
- 世界の組換えヒト凝固VIIaのタイプ別販売量（2018年-2023年）
- 世界の組換えヒト凝固VIIaのタイプ別売上（2018年-2023年）
- 世界の組換えヒト凝固VIIaのタイプ別価格

・用途別セグメント：先天性血友病、後天性血友病、その他
- 世界の組換えヒト凝固VIIaの用途別販売量（2018年-2023年）
- 世界の組換えヒト凝固VIIaの用途別売上（2018年-2023年）
- 世界の組換えヒト凝固VIIaの用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Novo Nordisk、LFB SA HEMA Biologics、AryoGen Pharmed、GENERIUM

・産業チェーンと販売チャネルの分析
- 組換えヒト凝固VIIa産業チェーン分析
- 組換えヒト凝固VIIaの主要原材料
- 組換えヒト凝固VIIaの販売チャネル
- 組換えヒト凝固VIIaのディストリビューター
- 組換えヒト凝固VIIaの主要顧客

・組換えヒト凝固VIIa市場ダイナミクス
- 組換えヒト凝固VIIaの業界動向
- 組換えヒト凝固VIIa市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
Highlights
The global Recombinant Human Coagulation VIIa market was valued at US$ 1133.8 million in 2022 and is anticipated to reach US$ 1467.3 million by 2029, witnessing a CAGR of 3.7% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Coagulation VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Coagulation VIIa.
The Recombinant Human Coagulation VIIa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Recombinant Human Coagulation VIIa market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Coagulation VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Coagulation VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Human Coagulation VIIa market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Coagulation VIIa market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Recombinant Human Coagulation VIIa and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Human Coagulation VIIa industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Coagulation VIIa.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Coagulation VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Recombinant Human Coagulation VIIa Market Overview
1.1 Product Overview and Scope of Recombinant Human Coagulation VIIa
1.2 Recombinant Human Coagulation VIIa Segment by Type
1.2.1 Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2023-2029)
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 Recombinant Human Coagulation VIIa Segment by Application
1.3.1 Global Recombinant Human Coagulation VIIa Market Value by Application: (2023-2029)
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Others
1.4 Global Recombinant Human Coagulation VIIa Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Coagulation VIIa Revenue 2018-2029
1.4.2 Global Recombinant Human Coagulation VIIa Sales 2018-2029
1.4.3 Global Recombinant Human Coagulation VIIa Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Human Coagulation VIIa Market Competition by Manufacturers
2.1 Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Human Coagulation VIIa Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Human Coagulation VIIa Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Human Coagulation VIIa Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Type & Application
2.7 Recombinant Human Coagulation VIIa Market Competitive Situation and Trends
2.7.1 Recombinant Human Coagulation VIIa Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Coagulation VIIa Players Market Share by Revenue
2.7.3 Global Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Coagulation VIIa Retrospective Market Scenario by Region
3.1 Global Recombinant Human Coagulation VIIa Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Human Coagulation VIIa Global Recombinant Human Coagulation VIIa Sales by Region: 2018-2029
3.2.1 Global Recombinant Human Coagulation VIIa Sales by Region: 2018-2023
3.2.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2024-2029
3.3 Global Recombinant Human Coagulation VIIa Global Recombinant Human Coagulation VIIa Revenue by Region: 2018-2029
3.3.1 Global Recombinant Human Coagulation VIIa Revenue by Region: 2018-2023
3.3.2 Global Recombinant Human Coagulation VIIa Revenue by Region: 2024-2029
3.4 North America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.4.1 North America Recombinant Human Coagulation VIIa Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Human Coagulation VIIa Sales by Country (2018-2029)
3.4.3 North America Recombinant Human Coagulation VIIa Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Coagulation VIIa Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Human Coagulation VIIa Sales by Country (2018-2029)
3.5.3 Europe Recombinant Human Coagulation VIIa Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Coagulation VIIa Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Human Coagulation VIIa Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Human Coagulation VIIa Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Coagulation VIIa Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Human Coagulation VIIa Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Human Coagulation VIIa Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Coagulation VIIa Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Coagulation VIIa Sales by Type (2018-2029)
4.1.1 Global Recombinant Human Coagulation VIIa Sales by Type (2018-2023)
4.1.2 Global Recombinant Human Coagulation VIIa Sales by Type (2024-2029)
4.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2018-2029)
4.2.1 Global Recombinant Human Coagulation VIIa Revenue by Type (2018-2023)
4.2.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2024-2029)
4.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Human Coagulation VIIa Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Human Coagulation VIIa Sales by Application (2018-2029)
5.1.1 Global Recombinant Human Coagulation VIIa Sales by Application (2018-2023)
5.1.2 Global Recombinant Human Coagulation VIIa Sales by Application (2024-2029)
5.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2018-2029)
5.2.1 Global Recombinant Human Coagulation VIIa Revenue by Application (2018-2023)
5.2.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2024-2029)
5.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Human Coagulation VIIa Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA HEMA Biologics
6.2.1 LFB SA HEMA Biologics Corporation Information
6.2.2 LFB SA HEMA Biologics Description and Business Overview
6.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2018-2023)
6.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Portfolio
6.2.5 LFB SA HEMA Biologics Recent Developments/Updates
6.3 AryoGen Pharmed
6.3.1 AryoGen Pharmed Corporation Information
6.3.2 AryoGen Pharmed Description and Business Overview
6.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Portfolio
6.3.5 AryoGen Pharmed Recent Developments/Updates
6.4 GENERIUM
6.4.1 GENERIUM Corporation Information
6.4.2 GENERIUM Description and Business Overview
6.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GENERIUM Recombinant Human Coagulation VIIa Product Portfolio
6.4.5 GENERIUM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Coagulation VIIa Industry Chain Analysis
7.2 Recombinant Human Coagulation VIIa Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Coagulation VIIa Production Mode & Process
7.4 Recombinant Human Coagulation VIIa Sales and Marketing
7.4.1 Recombinant Human Coagulation VIIa Sales Channels
7.4.2 Recombinant Human Coagulation VIIa Distributors
7.5 Recombinant Human Coagulation VIIa Customers
8 Recombinant Human Coagulation VIIa Market Dynamics
8.1 Recombinant Human Coagulation VIIa Industry Trends
8.2 Recombinant Human Coagulation VIIa Market Drivers
8.3 Recombinant Human Coagulation VIIa Market Challenges
8.4 Recombinant Human Coagulation VIIa Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Recombinant Human Coagulation VIIa Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Recombinant Human Coagulation VIIa Market Competitive Situation by Manufacturers in 2022
Table 4. Global Recombinant Human Coagulation VIIa Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Recombinant Human Coagulation VIIa Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Human Coagulation VIIa by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Coagulation VIIa as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Recombinant Human Coagulation VIIa Sales by Region (2018-2023) & (K Units)
Table 18. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2018-2023)
Table 19. Global Recombinant Human Coagulation VIIa Sales by Region (2024-2029) & (K Units)
Table 20. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2024-2029)
Table 21. Global Recombinant Human Coagulation VIIa Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2018-2023)
Table 23. Global Recombinant Human Coagulation VIIa Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2024-2029)
Table 25. North America Recombinant Human Coagulation VIIa Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Recombinant Human Coagulation VIIa Sales by Country (2018-2023) & (K Units)
Table 27. North America Recombinant Human Coagulation VIIa Sales by Country (2024-2029) & (K Units)
Table 28. North America Recombinant Human Coagulation VIIa Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Recombinant Human Coagulation VIIa Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Recombinant Human Coagulation VIIa Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Recombinant Human Coagulation VIIa Sales by Country (2018-2023) & (K Units)
Table 32. Europe Recombinant Human Coagulation VIIa Sales by Country (2024-2029) & (K Units)
Table 33. Europe Recombinant Human Coagulation VIIa Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Recombinant Human Coagulation VIIa Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Recombinant Human Coagulation VIIa Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Recombinant Human Coagulation VIIa Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Recombinant Human Coagulation VIIa Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Recombinant Human Coagulation VIIa Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Recombinant Human Coagulation VIIa Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Recombinant Human Coagulation VIIa Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Recombinant Human Coagulation VIIa Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Recombinant Human Coagulation VIIa Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Recombinant Human Coagulation VIIa Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Recombinant Human Coagulation VIIa Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2018-2023)
Table 51. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2024-2029)
Table 52. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2018-2023)
Table 53. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2024-2029)
Table 54. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2018-2023)
Table 57. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2024-2029)
Table 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2018-2023)
Table 59. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2024-2029)
Table 60. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2018-2023)
Table 61. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2024-2029)
Table 62. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2018-2023)
Table 63. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2024-2029)
Table 64. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2018-2023)
Table 67. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2024-2029)
Table 68. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2018-2023)
Table 69. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2024-2029)
Table 70. Novo Nordisk Corporation Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Novo Nordisk Recombinant Human Coagulation VIIa Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. LFB SA HEMA Biologics Corporation Information
Table 76. LFB SA HEMA Biologics Description and Business Overview
Table 77. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product
Table 79. LFB SA HEMA Biologics Recent Developments/Updates
Table 80. AryoGen Pharmed Corporation Information
Table 81. AryoGen Pharmed Description and Business Overview
Table 82. AryoGen Pharmed Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. AryoGen Pharmed Recombinant Human Coagulation VIIa Product
Table 84. AryoGen Pharmed Recent Developments/Updates
Table 85. GENERIUM Corporation Information
Table 86. GENERIUM Description and Business Overview
Table 87. GENERIUM Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. GENERIUM Recombinant Human Coagulation VIIa Product
Table 89. GENERIUM Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Recombinant Human Coagulation VIIa Distributors List
Table 93. Recombinant Human Coagulation VIIa Customers List
Table 94. Recombinant Human Coagulation VIIa Market Trends
Table 95. Recombinant Human Coagulation VIIa Market Drivers
Table 96. Recombinant Human Coagulation VIIa Market Challenges
Table 97. Recombinant Human Coagulation VIIa Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Human Coagulation VIIa
Figure 2. Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Recombinant Human Coagulation VIIa Market Share by Type in 2022 & 2029
Figure 4. Prefilled Syringe Product Picture
Figure 5. Vial Product Picture
Figure 6. Global Recombinant Human Coagulation VIIa Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Recombinant Human Coagulation VIIa Market Share by Application in 2022 & 2029
Figure 8. Congenital Hemophilia
Figure 9. Acquired Hemophilia
Figure 10. Others
Figure 11. Global Recombinant Human Coagulation VIIa Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Recombinant Human Coagulation VIIa Market Size (2018-2029) & (US$ Million)
Figure 13. Global Recombinant Human Coagulation VIIa Sales (2018-2029) & (K Units)
Figure 14. Global Recombinant Human Coagulation VIIa Average Price (US$/Unit) & (2018-2029)
Figure 15. Recombinant Human Coagulation VIIa Report Years Considered
Figure 16. Recombinant Human Coagulation VIIa Sales Share by Manufacturers in 2022
Figure 17. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Recombinant Human Coagulation VIIa Players: Market Share by Revenue in 2022
Figure 19. Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Recombinant Human Coagulation VIIa Sales Market Share by Country (2018-2029)
Figure 22. North America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2018-2029)
Figure 23. United States Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Recombinant Human Coagulation VIIa Sales Market Share by Country (2018-2029)
Figure 26. Europe Recombinant Human Coagulation VIIa Revenue Market Share by Country (2018-2029)
Figure 27. Germany Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Recombinant Human Coagulation VIIa Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Recombinant Human Coagulation VIIa Revenue Market Share by Region (2018-2029)
Figure 34. China Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Recombinant Human Coagulation VIIa Sales Market Share by Country (2018-2029)
Figure 44. Latin America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Recombinant Human Coagulation VIIa Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Recombinant Human Coagulation VIIa Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Recombinant Human Coagulation VIIa Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Recombinant Human Coagulation VIIa by Type (2018-2029)
Figure 54. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Type (2018-2029)
Figure 55. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Recombinant Human Coagulation VIIa by Application (2018-2029)
Figure 57. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Application (2018-2029)
Figure 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2018-2029)
Figure 59. Recombinant Human Coagulation VIIa Value Chain
Figure 60. Recombinant Human Coagulation VIIa Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 組換え活性型凝固第VII因子のグローバル市場展望 2023年-2029年：バイアル、プレフィルドシリンジ
  • 人間用凍結乾燥狂犬病ワクチン（ヒト二倍体細胞）のグローバル市場展望 2023年-2029年：バイアル、充填済み
  • アジュバント使用インフルエンザワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み
  • 10価肺炎球菌結合型ワクチンのグローバル市場展望 2023年-2029年：単回投与バイアル、プレフィルドシリンジ
  • 薬剤・装置複合製品のグローバル市場展望 2023年-2029年：薬剤溶出ステント、プレフィルドシリンジ、ウェアラブル注射器、インスリン注射器用薬剤、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8881 )"組換えヒト凝固VIIaの世界市場2023年：プレフィルドシリンジ、バイアル" (英文：Global Recombinant Human Coagulation VIIa Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。